In This Article
What TB-500 Actually Is
TB-500 is the synthetic version of thymosin beta-4, a peptide your body produces naturally. It's 43 amino acids long and found in virtually every cell and tissue - blood, muscle, skin, nerves, eyes. Your body makes it in higher concentrations wherever tissue is growing, healing, or remodelling.
The "TB" stands for thymosin beta. The "500" refers to the fraction it was isolated in during early research. What makes it interesting isn't that it exists - it's what it does. Thymosin beta-4 is one of your body's primary regulators of cell movement and tissue repair.
What It Does In Your Body
- Controls actin - the scaffolding inside cells - TB-500 binds to G-actin (the building blocks of the cellular skeleton) and controls when and where cells can move. This is fundamental to wound healing because cells need to physically migrate to injury sites
- Accelerates cell migration - in lab studies, TB-500 increased the speed of keratinocytes (skin cells), fibroblasts (connective tissue builders), and endothelial cells (blood vessel liners) moving into wounded areas by 2-3 fold
- Promotes new blood vessel growth - independently of its cell-movement role, it directly increases VEGF (vascular endothelial growth factor), which builds new blood vessels to supply healing tissue with oxygen and nutrients
- Reduces inflammation - it down-regulates NF-κB, one of the central switches in your body's inflammatory response, while simultaneously increasing anti-inflammatory signalling
- Prevents scar tissue formation - in animal studies, it organises connective tissue more effectively and reduces the appearance of myofibroblasts, the cells responsible for fibrosis and scarring
- Supports nerve repair - animal data suggests it promotes regrowth of damaged nerve fibres, including in the central nervous system
What The Animal Research Shows
The animal data on TB-500 is genuinely impressive in scope. Multiple research groups across different countries have tested it on different tissue types:
Wound Healing
The landmark study published in The FASEB Journal showed that both topical and injected TB-500 increased wound closure by 42% at 4 days and up to 61% at 7 days compared to untreated wounds. The healed tissue showed better collagen organisation and more blood vessel formation. These aren't marginal improvements.
Heart Tissue
After induced heart attacks in mice, TB-500 treatment improved cardiac function by promoting the migration of cardiac progenitor cells to damaged areas. The hearts showed better remodelling and less scar tissue. Several groups have replicated variations of this finding.
Tendons and Connective Tissue
Similar to BPC-157, TB-500 shows accelerated tendon repair in animal models. The difference: TB-500 appears to work primarily by getting cells to the injury site faster (migration), while BPC-157 appears to work more through blood flow and growth factor signalling. This is why some practitioners combine them.
Eye Injuries
One of the more advanced research areas. TB-500 (as thymosin beta-4) has been tested for corneal wounds, showing faster healing and reduced inflammation. This is one of the few areas where human clinical trial data actually exists.
The Human Data - Limited But Real
Unlike most peptides in this space, TB-500 (as thymosin beta-4) has some genuine human trial data, primarily in eye medicine:
- Corneal healing: A Phase 2 clinical trial (NCT00832091) tested thymosin beta-4 eye drops in patients with venous stasis ulcers. The compound showed wound healing benefits with a good safety profile
- RegeneRx Biopharmaceuticals has run multiple clinical programmes using thymosin beta-4 formulations for wound healing and eye conditions
But here's the critical gap: these studies used pharmaceutical-grade thymosin beta-4 in specific medical formulations. They're not equivalent to someone injecting research-grade TB-500 subcutaneously for sports recovery. The route, the purity, and the context are completely different.
TB-500 vs BPC-157 - The Comparison Everyone Asks About
How They're Different
- TB-500 works by moving cells to the injury. Its primary mechanism is actin regulation - it controls the cellular machinery that lets repair cells physically travel to damaged tissue
- BPC-157 works by creating the environment for repair. It increases blood flow (via nitric oxide), amplifies growth factor signalling, and activates the vagus nerve
- TB-500 has some human trial data (eye medicine). BPC-157 has essentially none
- TB-500 is systemic - it spreads throughout the body regardless of injection site. BPC-157 appears to have more localised effects near the injection site, though it also has systemic properties
- Both reduce inflammation but through different pathways - TB-500 via NF-κB suppression, BPC-157 via nitric oxide and vagal tone
This is why many practitioners use them together. In theory, one brings the repair cells to the injury (TB-500) while the other creates the optimal healing environment when they arrive (BPC-157). In theory. Nobody has tested this combination in a controlled human trial.
Who Actually Uses It
TB-500 is widely used in veterinary medicine, particularly in horse racing, where it's administered for tendon and ligament injuries. It's been banned by racing authorities in multiple countries precisely because it works well enough in horses to constitute an unfair advantage.
In the human world, it's used off-label by athletes, biohackers, and anti-ageing clinicians primarily for:
- Tendon and ligament injuries
- Muscle strains and tears
- Post-surgical recovery
- Chronic joint issues
- General tissue repair acceleration
Dosing - What The Community Uses
Standard community protocols (not medical advice):
- Loading phase: 2-2.5mg injected subcutaneously twice per week for 4-6 weeks
- Maintenance: 2-2.5mg once per week or once every two weeks
- Combined with BPC-157: Often run alongside 250-500mcg BPC-157 injected near the injury site
TB-500 is typically injected subcutaneously (under the skin) rather than intramuscularly. Because of its systemic distribution, the injection site matters less than with some other peptides.
The Purity Problem
TB-500 from research peptide suppliers varies enormously in quality. Independent testing has found products containing as little as 60% of the stated peptide content, with the remainder being synthesis by-products, degradation products, or fillers. Some contain bacterial endotoxins from poor manufacturing. If someone is going to use this, third-party testing certificates from a reputable analytical lab are essential - not the supplier's own certificate.
The Honest Bottom Line
TB-500 has more scientific credibility than most peptides in the recovery space. The mechanism is well-characterised, the animal data is consistent across multiple research groups, and there's at least some human clinical trial data (in eye medicine). It's not proven for the way most people use it - subcutaneous injection for sports injuries - but the biological rationale is sound. The biggest risks aren't the peptide itself but the quality of what you're actually injecting.
For the full peptide landscape, read the Complete Peptide Guide. For the companion compound, see the BPC-157 Deep Dive.
This article is for educational purposes only. It is not medical advice. Peptides discussed here may not be approved for human use in your country. Always consult a qualified medical professional before making any health decisions.